CancerScreen CDx Panels
CancerScreen CDx panel is an NGS assay designed to detect all types of variants from genes specifically associated with somatic cancer and also clinically significant sites, such as TERT promoter. By targeting the selected genes with high sensitivity and specificity enables cost-effective and efficient sequencing.
Also, if the gene of interest does not exist in the panel, it can be added separately through our gene add-on service
Celemic’s CancerScreen CDx Panels can also be accompanied by full Bioinformatics support; the report consists of the primary, secondary, and tertiary results for the in-depth understanding and interpretation of sequencing data.
Optimized Comprehensive Panel for Solid Cancer Analysis
The panel is designed to assess all major mutations for FDA approved therapies and all coding exons in each gene. Using the CancerScreen CDx panel, you can detect all mutation types, including SNV, Indel, Large Inde, CNV, rearrangements relevant to solid cancer in a single assay.
Performance Comparison with Competitor Product
- Higher on-target ratio, uniformity, coverage at 100X compared to competitor product over the target regions including exons and introns
Superior sensitivity and specificity for both DNA/RNA, even with FFPE or other low-quality clinical samples
CancerScreen CDx panel is suitable for detecting low-frequency and rare variants with high sequencing depths. With Celemics’ proprietary probe design technology, it provides superior capture performance even in so-called difficult to capture regions, such as GC-rich and homologous regions, regardless of the sample types, ranging from blood and tissue to poor-quality FFPE or ctDNA with the highest sensitivity and specificity.
Full Support from FASTQ to Clinical-grade Bioinformatics
Experience our full bioinformatic support and customizable services. Includes pathogenicity, drug-association information, and functional information of target genes.
Bioinformatics and Clinical Report Example
Rapid and Easy-to-use Workflow
Expedite sequencing with no compromise on data quality with rapid one-day protocol. Celemics provides simplified version of NGS workflow with no need for heavy instruments. The experimental procedure are also compatible with various automotive liquid handlers for your convenience.
Newly Developed Same-Day Workflow
» 20 hours
» 5-8 hours
|Product Name||CancerScreen CDx DNA Kit||CancerScreen CDx RNA Kit||CancerScreen CDx HRD Kit|
|Target size||73.4 kb||32.1 kb||69.4 kb|
|Mutation type||SNV, Indel, CNV, Rearrangement|
|Covered region||Whole CDS, Rearrangement|
|Sample Type||FFPE, Fresh tissue, etc.|
|Platform||All sequencers from Illumina and Thermo Fisher|
|Bioinformatics Support||① Primary Analysis: FASTQ to annotated VCF
② Secondary Analysis: CNV, Large InDel, TMB & MSI
③ Tertiary Analysis: Clinical interpretation
Visualization Curation (Heatmap, CNV visualization, Statistical analysis, etc.)
Specification - Gene List
- 22 genes | Gene count
- 73.4 kb | Target Size
- 9 genes | Gene count
- 32.1 kb | Target Size
- 15 genes | Gene count
- 69.4 kb | Target Size
Flyer_CancerScreen CDx Panel
Product Overview] Celemics Target Enrichment Panel Overview
[Catalogue] Celemics Products & Service Catalogue_All Products & Service
Safety Data Sheets
MSDS_CancerScreen CDx Panels_Illumina_Enzymeplus
MSDS_CancerScreen CDx Panels_Illumina
MSDS_CancerScreen CDx Panels_Thermo Fisher
MSDS_CancerScreen CDx Panels_MGI_EnzymePlus
MSDS_CancerScreen CDx Panels_MGI
Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel
Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.
Investig Clin Urol
Germline pathogenic variants in unselected Korean men with prostate cancer
So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.
Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers
Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.
BMC Medical Genomics
A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report
Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.